Ignite Creation Date:
2025-12-24 @ 5:04 PM
Ignite Modification Date:
2026-01-09 @ 7:50 AM
Study NCT ID:
NCT03644550
Status:
TERMINATED
Last Update Posted:
2021-12-02
First Post:
2018-08-22
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-12-04
Start Date Type:
ACTUAL
Primary Completion Date:
2020-08-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-11-02
Completion Date Type:
ACTUAL
First Submit Date:
2018-08-22
First Submit QC Date:
None
Study First Post Date:
2018-08-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2021-10-13
Results First Submit QC Date:
None
Results First Post Date:
2021-12-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-11-03
Last Update Post Date:
2021-12-02
Last Update Post Date Type:
ACTUAL